Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients

Letermovir is indicated for prophylaxis of cytomegalovirus infection and disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Two‐stage population pharmacokinetic (PK) modeling of letermovir was conducted to support dose rationale and evaluate the impact of intrinsic/extrinsic...

Descripción completa

Detalles Bibliográficos
Autores principales: Prohn, Marita, Viberg, Anders, Zhang, Da, Dykstra, Kevin, Davis, Casey, Macha, Sreeraj, Sabato, Philip, de Alwis, Dinesh, Iwamoto, Marian, Fancourt, Craig, Cho, Carolyn R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7965833/
https://www.ncbi.nlm.nih.gov/pubmed/33440077
http://dx.doi.org/10.1002/psp4.12593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7965833/
https://www.ncbi.nlm.nih.gov/pubmed/33440077
http://dx.doi.org/10.1002/psp4.12593

Ejemplares similares